{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:03:04Z","timestamp":1771272184905,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Roche Diagnostics Saudi Arabia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03463-6","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:01:09Z","timestamp":1766563269000},"page":"750-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guideline-Based Elevated NT-proBNP Among Asymptomatic Adults with Diabetes in Saudi Arabia: Prevalence and Real-World Clinical Correlates"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-3196","authenticated-orcid":false,"given":"Ayman","family":"Al Hayek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar A.","family":"Borai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed A.","family":"Alhabeeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael M.","family":"Zahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malak A.","family":"Mashali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A.","family":"Dawish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"3463_CR1","unstructured":"IDF. Saudi Arabia. International Diabetes Federation. 2024. https:\/\/idf.org\/our-network\/regions-and-members\/middle-east-and-north-africa\/members\/saudi-arabia\/. Accessed 20 August 2025."},{"key":"3463_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny HC, Abel ED. Heart failure in type\u00a02 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circ Res. 2019;124:121\u201341. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311371.","journal-title":"Circ Res"},{"key":"3463_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.37616\/2212-5043.1407","volume":"36","author":"W Alhabeeb","year":"2024","unstructured":"Alhabeeb W, Elasfar A, Kinsara AJ, et al. A Saudi Heart Association position statement on cardiovascular diseases and diabetes mellitus. J Saudi Heart Assoc. 2024;36:385\u2013407. https:\/\/doi.org\/10.37616\/2212-5043.1407.","journal-title":"J Saudi Heart Assoc"},{"key":"3463_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure. J Card Fail. 2021;27:387\u2013413. https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.022.","journal-title":"J Card Fail"},{"key":"3463_CR5","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"3463_CR6","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"ElSayed NA, Aleppo G, Bannuru RR, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2024;47:S179-218. https:\/\/doi.org\/10.2337\/dc24-S010.","journal-title":"Diabetes Care"},{"key":"3463_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.72576","volume":"16","author":"A Joshi","year":"2024","unstructured":"Joshi A, Dalal D, Patil S, et al. Screening for occult heart failure in type\u00a02 diabetes mellitus using NT-proBNP: real-world evidence from a tertiary care center in India. Cureus. 2024;16:e72576. https:\/\/doi.org\/10.7759\/cureus.72576.","journal-title":"Cureus"},{"key":"3463_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jchf.2023.01.012","volume":"11","author":"JW Cunningham","year":"2023","unstructured":"Cunningham JW, Claggett BL, Solomon SD, Vaduganathan M. Natriuretic peptide-based screening for pre-heart failure in patients with type\u00a02 diabetes across the United States. JACC: Heart Failure. 2023;11:724\u20136. https:\/\/doi.org\/10.1016\/j.jchf.2023.01.012.","journal-title":"JACC: Heart Failure"},{"key":"3463_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ehf2.14149","volume":"10","author":"S Aoki","year":"2023","unstructured":"Aoki S, Yamagishi K, Kihara T, et al. Risk factors for pre-heart failure or symptomatic heart failure based on NT-proBNP. ESC Heart Fail. 2023;10:90\u20139. https:\/\/doi.org\/10.1002\/ehf2.14149.","journal-title":"ESC Heart Fail"},{"key":"3463_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110923","volume":"205","author":"M Witkowski","year":"2023","unstructured":"Witkowski M, Wu Y, Wilson Tang WH, Hazen SL. NT-proBNP and cardiovascular event risk in individuals with prediabetes undergoing cardiovascular evaluation. Diabetes Res Clin Pract. 2023;205:110923. https:\/\/doi.org\/10.1016\/j.diabres.2023.110923.","journal-title":"Diabetes Res Clin Pract"},{"key":"3463_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2025.08.019","author":"Y Mori","year":"2025","unstructured":"Mori Y, Natori S, Arai T, Kakuya F, Fukuma S. Biomarker-based pre-heart failure screening in a middle-aged rural population. J Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.jjcc.2025.08.019.","journal-title":"J Cardiol"},{"key":"3463_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s00125-024-06299-x","volume":"68","author":"RCW Ma","year":"2025","unstructured":"Ma RCW, Tam CHT, Hou Y, et al. NT-proBNP improves prediction of cardiorenal complications in type\u00a02 diabetes: the Hong Kong Diabetes Biobank. Diabetologia. 2025;68:342\u201356. https:\/\/doi.org\/10.1007\/s00125-024-06299-x.","journal-title":"Diabetologia"},{"key":"3463_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S1262-3636(07)70232-X","volume":"31","author":"S Beer","year":"2005","unstructured":"Beer S, Golay S, Bardy D, et al. Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in type\u00a02 diabetic patients with vascular complications. Diabetes Metab. 2005;31:567\u201373. https:\/\/doi.org\/10.1016\/S1262-3636(07)70232-X.","journal-title":"Diabetes Metab"},{"key":"3463_CR14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1253\/circj.CJ-24-0774","volume":"89","author":"S Miyazaki","year":"2025","unstructured":"Miyazaki S, Inaba S, Higashi H, et al. Validation of N-terminal pro B-type natriuretic peptide threshold for early detection of pre-heart failure in a general Japanese population- Toon Health Study. Circ J. 2025;89:966\u201372. https:\/\/doi.org\/10.1253\/circj.CJ-24-0774.","journal-title":"Circ J"},{"key":"3463_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12933-024-02378-w","volume":"23","author":"P Gouda","year":"2024","unstructured":"Gouda P, Liu Y, Butler J, et al. Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy. Cardiovasc Diabetol. 2024;23:281. https:\/\/doi.org\/10.1186\/s12933-024-02378-w.","journal-title":"Cardiovasc Diabetol"},{"key":"3463_CR16","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025. Diabet Care. 2025;48:S207\u201338. https:\/\/doi.org\/10.2337\/dc25-S010.","journal-title":"Diabet Care"},{"key":"3463_CR17","doi-asserted-by":"publisher","DOI":"10.57187\/s.4000","volume":"154","author":"M Paul","year":"2024","unstructured":"Paul M, Eggerschwiler A, Meyer G, et al. Recommendations for early identification of heart failure in patients with diabetes: consensus statement of the Swiss Society of Endocrinology and Diabetology and the heart failure working group of the Swiss Society of Cardiology. Swiss Med Wkly. 2024;154:4000. https:\/\/doi.org\/10.57187\/s.4000.","journal-title":"Swiss Med Wkly"},{"key":"3463_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","volume":"15","author":"P Welsh","year":"2022","unstructured":"Welsh P, Campbell RT, Mooney L, et al. Reference ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circ Heart Fail. 2022;15:e009427. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009427.","journal-title":"Circ Heart Fail"},{"key":"3463_CR19","doi-asserted-by":"publisher","first-page":"1395630","DOI":"10.3389\/fendo.2024.1395630","volume":"15","author":"H Sabbour","year":"2025","unstructured":"Sabbour H, Almahmeed W, Alawadi F, et al. Emirates consensus recommendations on cardiovascular risk management in type\u00a02 diabetes. Front Endocrinol. 2025;15:1395630. https:\/\/doi.org\/10.3389\/fendo.2024.1395630.","journal-title":"Front Endocrinol"},{"key":"3463_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2020.11.063","volume":"77","author":"A Hussain","year":"2021","unstructured":"Hussain A, Sun W, Deswal A, et al. Association of NT-ProBNP, blood pressure, and cardiovascular events. J Am Coll Cardiol. 2021;77:559\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.063.","journal-title":"J Am Coll Cardiol"},{"key":"3463_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132239","volume":"410","author":"S Banjar","year":"2024","unstructured":"Banjar S, Alharbi S, Omer I, et al. Effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and structural changes following myocardial infarction: a systematic review and meta-analysis. Int J Cardiol. 2024;410:132239. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132239.","journal-title":"Int J Cardiol"},{"key":"3463_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109064","volume":"39","author":"A Al Hayek","year":"2025","unstructured":"Al Hayek A, Klonoff DC, Al Zahrani WM, Ibrahim SE, Al Dawish MA. Evaluating the effect of semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type\u00a01 diabetes: a two-year real-world data study. J Diabetes Complications. 2025;39:109064. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109064.","journal-title":"J Diabetes Complications"},{"key":"3463_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2022.02.010","volume":"28","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Card Fail. 2022;28:e1-167. https:\/\/doi.org\/10.1016\/j.cardfail.2022.02.010.","journal-title":"J Card Fail"},{"key":"3463_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108410","volume":"37","author":"A Ceriello","year":"2023","unstructured":"Ceriello A, Lalic N, Montanya E, et al. NT-proBNP point-of-care measurement as a screening tool for heart failure and CVD risk in type\u00a02 diabetes with hypertension. J Diabetes Complications. 2023;37:108410. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108410.","journal-title":"J Diabetes Complications"},{"key":"3463_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijcard.2022.03.032","volume":"357","author":"A Avogaro","year":"2022","unstructured":"Avogaro A, Azzolina D, Gregori D, De Kreutzenberg S, Fadini GP, Mannucci E. The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis. Int J Cardiol. 2022;357:123\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2022.03.032.","journal-title":"Int J Cardiol"},{"key":"3463_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12933-024-02391-z","volume":"23","author":"M Landolfo","year":"2024","unstructured":"Landolfo M, Spannella F, Giulietti F, et al. Detecting heart stress using NT-proBNP in patients with type\u00a02 diabetes mellitus and hypertension or high-normal blood pressure: a cross-sectional multicentric study. Cardiovasc Diabetol. 2024;23:297. https:\/\/doi.org\/10.1186\/s12933-024-02391-z.","journal-title":"Cardiovasc Diabetol"},{"key":"3463_CR27","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","volume":"62","author":"M Huelsmann","year":"2013","unstructured":"Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease). J Am Coll Cardiol. 2013;62:1365\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.069.","journal-title":"J Am Coll Cardiol"},{"key":"3463_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"M Ledwidge","year":"2013","unstructured":"Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66\u201374. https:\/\/doi.org\/10.1001\/jama.2013.7588.","journal-title":"JAMA"},{"key":"3463_CR29","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","volume":"83","author":"TM Maddox","year":"2024","unstructured":"Maddox TM, Januzzi JL, Allen LA, et al. 2024. ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83:1444\u201388. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.024.","journal-title":"J Am Coll Cardiol"},{"key":"3463_CR30","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1080\/13696998.2023.2264722","volume":"26","author":"E Walter","year":"2023","unstructured":"Walter E, Arrigo M, Allerstorfer S, Marty P, H\u00fclsmann M. Cost-effectiveness of NT-proBNP-supported screening of chronic heart failure in patients with or without type\u00a02 diabetes in Austria and Switzerland. J Med Econ. 2023;26:1287\u2013300. https:\/\/doi.org\/10.1080\/13696998.2023.2264722.","journal-title":"J Med Econ"},{"key":"3463_CR31","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1002\/ehf2.14471","volume":"10","author":"R Walkley","year":"2023","unstructured":"Walkley R, Allen AJ, Cowie MR, Maconachie R, Anderson L. The cost-effectiveness of NT-proBNP for assessment of suspected acute heart failure in the emergency department. ESC Heart Fail. 2023;10:3276\u201386. https:\/\/doi.org\/10.1002\/ehf2.14471.","journal-title":"ESC Heart Fail"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03463-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03463-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03463-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:49Z","timestamp":1771268629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03463-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3463"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03463-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ayman Al Hayek, Anwar A. Borai, Waleed A. Alhabeeb, Wael M. Zahrani, Malak A. Mashali, and Mohammed A. Dawish has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approval for the study protocol was granted by the Institutional Review Board at Prince Sultan Military Medical City, Saudi Arabia (Protocol number E-2465-HP-01-R079; Series of 2024). The individual patient consent requirement was not required, given the retrospective design and deidentified data use. Patient confidentiality was strictly maintained, and all data were anonymized throughout the study. The Institutional Review Board approved a waiver of informed consent due to the retrospective nature of the study. No identifiable personal information was accessed, stored, or reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}